Related Experiment Video
Updated: Nov 17, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
The Importance of STK11/LKB1 Assessment in Non-Small Cell Lung Carcinomas
Baharia Mograbi1, Simon Heeke2, Paul Hofman1,3,4
1Centre Antoine Lacassagne, CNRS, FHU OncoAge, Team 4, INSERM, IRCAN, Université Côte d'Azur, 06000 Nice, France.
Abstract:
Despite the recent implementation of immunotherapy as a single treatment or in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer (NSCLC), many patients do not benefit from this regimen due to primary treatment resistance or toxicity. Consequently, there is an urgent need to develop efficient biomarkers that can select patients who will benefit from immunotherapy thereby providing the appropriate treatment and avoiding toxicity. One of the biomarkers recently described for the stratification of NSCLC patients undergoing immunotherapy are mutations in STK11/LKB1, which are often associated with a lack of response to immunotherapy in some patients. Therefore, the purpose of this review is to describe the different cellular mechanisms associated with STK11/LKB1 mutations, which may explain the lack of response to immunotherapy. Moreover the review addresses the co-occurrence of additional mutations that may influence the response to immunotherapy and the current clinical studies that have further explored STK11/LKB1 as a predictive biomarker. Additionally this work includes the opportunities and limitations to look for the STK11/LKB1 status in the therapeutic strategy for NSCLC patients.
Insights
Mutations in STK11/LKB1 impact immunotherapy response in non-small cell lung cancer (NSCLC). Understanding these genetic changes helps predict treatment effectiveness and avoid toxicity in NSCLC patients.
Area of Science:
- Oncology
- Genetics
- Immunotherapy
Background:
- Immunotherapy is a key treatment for advanced non-small cell lung cancer (NSCLC), often combined with chemotherapy.
- However, many NSCLC patients exhibit primary resistance or toxicity, necessitating better predictive biomarkers.
- STK11/LKB1 mutations are emerging as important factors influencing immunotherapy response in NSCLC.
Purpose of the Study:
- To review cellular mechanisms underlying STK11/LKB1 mutations and their link to immunotherapy resistance in NSCLC.
- To explore co-occurring mutations that modify immunotherapy response.
- To summarize current clinical studies and the role of STK11/LKB1 as a predictive biomarker in NSCLC.
Main Methods:
- Literature review of cellular mechanisms.
- Analysis of co-occurring mutations impacting immunotherapy.
- Summary of clinical trials investigating STK11/LKB1 in NSCLC.
Main Results:
- STK11/LKB1 mutations are associated with reduced response to immunotherapy in certain NSCLC patient groups.
- Co-mutations can further modulate immunotherapy efficacy.
- Clinical studies are actively investigating STK11/LKB1 status for patient stratification.
Conclusions:
- STK11/LKB1 status presents both opportunities and limitations as a predictive biomarker for NSCLC immunotherapy.
- Understanding these mutations is crucial for optimizing NSCLC treatment strategies.
- Further research is needed to fully integrate STK11/LKB1 testing into clinical practice for NSCLC.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
